M&A Deal Summary

Sigma-Aldrich Acquires JRH Biosciences

On February 28, 2005, Sigma-Aldrich acquired life science company JRH Biosciences from CSL for 370M USD

Acquisition Highlights
  • This is Sigma-Aldrich’s 3rd transaction in the Life Science sector.
  • This is Sigma-Aldrich’s largest (disclosed) transaction.
  • This is Sigma-Aldrich’s 2nd transaction in the United States.

M&A Deal Summary
Date 2005-02-28
Target JRH Biosciences
Sector Life Science
Buyer(s) Sigma-Aldrich
Sellers(s) CSL
Deal Type Divestiture
Deal Value 370M USD

Target

JRH Biosciences

Lenexa, United States
JRH, headquartered in Lenexa, Kansas, has major manufacturing facilities and/or serum collection and processing centers in Caseyville, Illinois, Lenexa, Kansas, and Denver, Pennsylvania in the United States; Andover in the United Kingdom; and Brisbane and Brooklyn in Australia. JRH's product lines include sera, cell culture media used in the production of therapeutic proteins, reagent growth factors and biological material containers. JRH has approximately 400 employees.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sigma-Aldrich

St. Louis, Missouri, United States
Category Company
Founded 1951
Sector Life Science
Employees9,800
Revenue 2.8B USD (2014)
DESCRIPTION

Sigma-Aldrich Corp. is a life science and high technology company whose biochemical, organic chemical products, kits, and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university, and government institutions, hospitals, and industry.

DEAL STATS #
Overall 3 of 13
Sector (Life Science) 3 of 10
Type (Divestiture) 1 of 3
Country (United States) 2 of 9
Year (2005) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2004-06-22 Tetrionics

Madison, Wisconsin, United States

Tetrionics supplies pharmaceutical development market with high purity vitamin D analogs. Its services include synthesis and scale up, analytical chemistry, regulatory support and current good manufacturing practice (cGMP) of active pharmaceutical ingredients across a broad range of structural classes of molecules with a strong emphasis on high potency and cytotoxic compounds.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-05-03 Iropharm

Dublin, Delaware, Ireland

Iropharm, which operates a U.S. Food and Drug Administration-inspected manufacturing facility in Arklow near Dublin, is a producer of high-quality fine chemicals for the pharmaceutical industry. The company makes both intermediate and active ingredients under current Good Manufacturing Practices (cGMP).

Buy -

Seller(S) 1

SELLER

CSL

Melobourne, Australia
Category Company
Founded 1916
Sector Life Science
Employees32,698
Revenue 14.7B USD (2024)
DESCRIPTION

CSL is a manufacturer and marketer of pharmaceutical and diagnostic products, cell culture media and human plasma fractions. CSL was founded in 1916 and is based in Melbourne, Australia.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
Country (United States) 1 of 2
Year (2005) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-08-12 Talecris Biotherapeutics Holdings Corp

Research Triangle Park, North Carolina, United States

Talecris Biotherapeutics Holdings Corp. is a pharmaceutical Development and Manufacturing company.

Buy $3.1B
Mergr

Product

Company

Legal